US FDA

Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceutical, Los Angeles, CA. 483 Issued 03/23/2017

ByDossier Experts June 20, 2025

Task Description Request Please post to the 2017 Pharmacy Inspections and Related Records Web page
Record Date 03/23/2017
FEI Number 3013341563
Firm Name Fusion IV Pharmaceuticals Inc. dba Axia Ph

US FDA

What You Should Know about Eye Drops
ByDossier Experts December 1, 2025
Ophthalmic drug products, such as eye drops, pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses. Any drug used in the eyes must be sterile to reduce the risk of infection. Eye drops are available by prescription or sold as OTCs.
Share this:
Facebook
X
Read More What You Should Know about Eye Drops
US FDA

FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
ByDossier Experts August 27, 2025
FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
Share this:
Facebook
X
Read More FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events
US FDA

Catheter Recall Expansion: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters
ByDossier Experts March 5, 2026
Certain reprocessed catheters may contain residual particulates that could cause infection, embolism, or thrombosis
Share this:
Facebook
X
Read More Catheter Recall Expansion: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters
US FDA

Rhino 69 Gummy may be harmful due to hidden drug ingredient
ByDossier Experts July 22, 2025
The Food and Drug Administration is advising consumers not to purchase or use Rhino 69 Gummy, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.
Share this:
Facebook
X
Read More Rhino 69 Gummy may be harmful due to hidden drug ingredient
US FDA

Activities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805
ByDossier Experts March 5, 2026
Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).
Share this:
Facebook
X
Read More Activities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805
US FDA

Sun Pharmaceuticals Medicare Ltd. 9/19/2025
ByDossier Experts December 29, 2025
Record Date: 9/19/2025
Entity Name: Sun Pharmaceuticals Medicare Ltd.
FEI Number: 3002957541
Record Type: 483
Country: India
Establishment Type: Sterile Drug Manufacturer
Share this:
Facebook
X
Read More Sun Pharmaceuticals Medicare Ltd. 9/19/2025

Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceutical, Los Angeles, CA. 483 Issued 03/23/2017

Related

What You Should Know about Eye Drops

FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events

Catheter Recall Expansion: Medline Industries Removes Reprocessed Electrophysiology and Ultrasound Catheters

Rhino 69 Gummy may be harmful due to hidden drug ingredient

Activities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805

Sun Pharmaceuticals Medicare Ltd. 9/19/2025

Quick Links

Our Services

Legal & Info

Contact

Share this:

Related

Similar Posts

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Quick Links

Our Services

Legal & Info

Contact